Dawn Halkuff Sells 20,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Dawn Halkuff sold 20,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $121,800.00. Following the sale, the director directly owned 95,000 shares of the company’s stock, valued at $578,550. This represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Trading Up 0.5%

XERS stock opened at $6.18 on Friday. The business has a fifty day moving average price of $6.10 and a 200 day moving average price of $6.59. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $10.08. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of 103.00 and a beta of 0.78. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares during the period. Geode Capital Management LLC grew its stake in shares of Xeris Biopharma by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after purchasing an additional 135,815 shares during the period. State Street Corp grew its stake in shares of Xeris Biopharma by 10.1% during the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares during the period. Qube Research & Technologies Ltd grew its stake in shares of Xeris Biopharma by 6.0% during the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on XERS shares. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xeris Biopharma presently has a consensus rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.